ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Ablynx's vobarilizumab trial fails and sees two patient deaths in systemic lupus erythematosus
March 27, 2018Ablynx has revealed that its interleukin 6 pathway via its IL-6 receptor (IL-6R) vobarilizumab failed to meet its primary endpoint in a Phase 2 trial, presenting implications for Sanofi who will acquire the drug following its agreement to buy the firm for
Pharma Sources Insight January 2025
